Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi PharmaTech Makes Clinical-Stage CRO Acquisition

publication date: Oct 24, 2011
WuXi PharmaTech will acquire two related China clinical-stage CROs so that the company can expand its offerings to include clinical-stage services for its clients. Previously, WuXi’s offerings were limited to pre-clinical drug development and contract manufacturing. In August, Dr. Ge Li, CEO of WuXi, announced the company would move into clinical-stage services through a “combination of organic growth and acquisitions." Positioning the expansion as a natural outgrowth of its pre-clinical work, Dr. Li said clients were requesting help in obtaining SFDA approval for their new products. More details....

Stock Symbol: (NYSE: WX)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital